Patents by Inventor Gemma Fabrias

Gemma Fabrias has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11426371
    Abstract: The present application provides novel compositions and methods for treating acute myeloid leukemia (AML). Compounds of the invention are acid ceramidase inhibitors, reduce AML cell viability, inhibit AML cell proliferation, increase cell death of AML cells, and induce apoptosis in AML cells. A primary compound of the invention is SACLAC: 2-chloro-N-((2S,3R)-1,3-dihydroxyoctadecan-2-yl)acetamide. The bromine analog of SACLAC (SABRAC: 2-bromo-N-((2S,3R)-1,3-dihydroxyoctadecan-2-yl)acetamide) is also useful for treating AML. SACLAC has much better activity than other know drugs used to treat AML.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: August 30, 2022
    Assignees: University of Virginia Patent Foundation, Universität de Barcelona, Consejo Superior de Investigaciones Cientificas (CSIC)
    Inventors: Thomas P. Loughran, Jr., Gemma Fabrias, Jose Luis Abad, Josefina Casas, David J. Feith, Su-Fern Tan, Jennifer M. Pearson, Antonio Delgado Cirilo
  • Publication number: 20200276138
    Abstract: The present application provides novel compositions and methods for treating acute myeloid leukemia (AML). Compounds of the invention are acid ceramidase inhibitors, reduce AML cell viability, inhibit AML cell proliferation, increase cell death of AML cells, and induce apoptosis in AML cells. A primary compound of the invention is SACLAC: 2-chloro-N-((2S,3R)-1,3-dihydroxyoctadecan-2-yl)acetamide. The bromine analog of SACLAC (SABRAC: 2-bromo-N-((2S,3R)-1,3-dihydroxyoctadecan-2-yl)acetamide) is also useful for treating AML. SACLAC has much better activity than other know drugs used to treat AML.
    Type: Application
    Filed: April 27, 2018
    Publication date: September 3, 2020
    Inventors: Thomas P. Loughran, JR., Gemma Fabrias, Jose Luis Abad, Josefina Casas, David J. Feith, Su-Fern Tan, Jennifer M. Pearson, Antonio Delgado Cirilo
  • Patent number: 7537918
    Abstract: The invention relates to a process of producing polyunsaturated fatty acids through the incorporation of olefinic or acetylenic fatty acids with a chain length of 13-18 carbon atoms as substrates with a haploid or diploid wild strain of Saccharomyces cerevisiae yeast W 303a or ?Elo1, which can be used to generate a novel linkage with configuration Z in position 9 of said substrates. The novel desaturation is only produced if the original unsaturation in the administered products has configuration E or is an acetylene. Moreover, if the original linkage has configuration Z, the substrate is recovered unaltered.
    Type: Grant
    Filed: March 31, 2005
    Date of Patent: May 26, 2009
    Assignee: Consejo Superior De Investigaciones Cientificas
    Inventors: Francisco Camps Díez, Sergio Rodríguez Ropero, Gemma Fabriàs Domingo, Benjamin Piña Capo
  • Publication number: 20050227339
    Abstract: The invention relates to a process of producing polyunsaturated fatty acids through the incorporation of olefinic or acetylenic fatty acids with a chain length of 13-18 carbon atoms as substrates with a haploid or diploid wild strain of Saccharomyces cerevisiae yeast W 303a or ?Elo1, which can be used to generate a novel linkage with configuration Z in position 9 of said substrates. The novel desaturation is only produced if the original unsaturation in the administered products has configuration E or is an acetylene. Moreover, if the original linkage has configuration Z, the substrate is recovered unaltered.
    Type: Application
    Filed: March 31, 2005
    Publication date: October 13, 2005
    Inventors: Francisco Camps Diez, Sergio Rodriguez Ropero, Gemma Fabrias Domingo, Benjamin Pina Capo